Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment

Acta Ophthalmologica

Volumn 92, Issue 7, 2014, Pages 675-681

  Tuuminen, Raimo ^a   Sahanne, Sari ^a   Loukovaara, Sirpa ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

angiopoietin 2; diabetic retinopathy; HMG CoA reductase inhibitors; simvastatin; VEGF; vitrectomy

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ERYTHROPOIETIN; GELATINASE A; GELATINASE B; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANGPT2 PROTEIN, HUMAN; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD LEVEL; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVITREAL LEVEL; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; VITRECTOMY; VITREOUS BODY; ZYMOGRAPHY; AGED; COMPLICATION; DIABETIC RETINOPATHY; METABOLISM;

ADULT; AGED; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIETIN; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MACULAR EDEMA; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84927171401     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12363     Document Type: Article

References (43)

1. van Agtmaal EL, Bierings R, Dragt BS, et al., (2012): The shear stress-induced transcription factor KLF2 affects dynamics and angiopoietin-2 content of Weibel-Palade bodies. PLoS ONE 7: e38399.
2. Aiello LP, Avery RL, Arrigg PG, et al., (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
3. Al-Shabrawey M, Bartoli M, El-Remessy AB, et al., (2008): Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 49: 3231-3238.
4. Bartoli M, Al-Shabrawey M, Labazi M, et al., (2009): HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50: 4934-4940.
5. Chew EY, Ambrosius WT, Davis MD, et al., (2010): Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363: 233-244.
6. Collins R, Armitage J, Parish S, Sleigh P, &, Peto R, (2003): MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
7. Danaei G, Tavakkoli M, &, Hernan MA, (2012): Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175: 250-262.
8. Gordon B, Chang S, Kavanagh M, et al., (1991): The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 112: 385-391.
9. Hammes HP, Lin J, Wagner P, et al., (2004): Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53: 1104-1110.
10. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al., (1998): Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719.
11. Ho C, Hsu YC, Tseng CC, Wang FS, Lin CL, &, Wang JY, (2008): Simvastatin alleviates diabetes-induced VEGF-mediated nephropathy via the modulation of Ras signaling pathway. Ren Fail 30: 557-565.
12. Joussen AM, Poulaki V, Le ML, et al., (2004): A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18: 1450-1452.
13. Kawahara S, Hata Y, Kita T, et al., (2008): Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. Diabetes 57: 2784-2793.
14. Ko ML, Chen CF, Peng PH, &, Peng YH, (2011): Simvastatin upregulates Bcl-2 expression and protects retinal neurons from early ischemia/reperfusion injury in the rat retina. Exp Eye Res 93: 580-585.
15. Ko F, Vitale S, Chou CF, Cotch MF, Saaddine J, &, Friedman DS, (2012): Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999-2002 and 2005-2008. JAMA 308: 2361-2368.
16. Koh KK, (2000): Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47: 648-657.
17. Kowluru RA, (2010): Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras. Invest Ophthalmol Vis Sci 51: 4320-4326.
18. Lee SG, Kim JL, Lee HK, et al., (2011): Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes. Graefes Arch Clin Exp Ophthalmol 249: 389-397.
19. Li X, Cai Y, Wang YS, et al., (2012): Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cells. PLoS ONE 7: e47600.
20. Liao JK, &, Laufs U, (2005): Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45: 89-118.
21. Lohi J, Lehti K, Westermarck J, Kahari VM, &, Keski-Oja J, (1996): Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 239: 239-247.
22. Loukovaara S, Lehti K, Robciuc A, et al., (2013): Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol Scand 91: 531-539. 2012, doi: 10.1111/j.1755-3768.2012.02473.x
23. Marcus MW, Muskens RP, Ramdas WD, et al., (2012): Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS ONE 7: e29724.
24. Medina RJ, O'Neill CL, Devine AB, Gardiner TA, &, Stitt AW, (2008): The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS ONE 3: e2584.
25. Miller JW, Couter J, Strauss EC, &, Ferrara N, (2013): Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 120: 106-114.
26. Miyahara S, Kiryu J, Yamashiro K, et al., (2004): Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol 164: 1697-1706.
27. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, &, Galper JB, (2002): 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150.
28. Qin J, Zhang Z, Liu J, et al., (2003): Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 64: 565-571.
29. Rangasamy S, Srinivasan R, Maestas J, McGuire PG, &, Das A, (2011): A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 52: 3784-3791.
30. Sen K, Misra A, Kumar A, &, Pandey RM, (2002): Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 56: 1-11.
31. Shepherd J, Barter P, Carmena R, et al., (2006): Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29: 1220-1226.
32. Takemoto M, &, Liao JK, (2001): Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719.
33. Tuuminen R, &, Loukovaara S, (2013): Increased Intravitreal Angiopoietin-2 Levels Associated With Retinal Vein Occlusion. Acta Ophthalmol Scand [Epub ahead of print].
34. Tuuminen R, Syrjala S, Krebs R, et al., (2011): Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protection. Circulation 124: 1138-1150.
35. Tuuminen R, Nykanen A, Saharinen P, et al., (2013): Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function. Am J Transplant 3: 2019-2034. doi: 10.1111/ajt.12315
36. Undas A, Celinska-Lowenhoff M, Stepien E, Nizankowski R, Tracz W, &, Szczeklik A, (2006): Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury. Thromb Haemost 95: 1045-1047.
37. Vincent L, Soria C, Mirshahi F, et al., (2002): Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22: 623-639.
38. Weis M, Heeschen C, Glassford AJ, &, Cooke JP, (2002): Statins have biphasic effects on angiogenesis. Circulation 105: 739-745.
39. Yao XM, Ye SD, Zai Z, et al., (2010): Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression. J Endocrinol Invest 33: 292-296.
40. Zambarakji HJ, Nakazawa T, Connolly E, et al., (2006): Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci 47: 2623-2631.
41. Zhang W, &, Yan H, (2012): Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats. Exp Eye Res 105: 1-8.
42. Zhang L, Gong D, Li S, &, Zhou X, (2012): Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis 223: 78-85.
43. Zheng Z, Chen H, Wang H, et al., (2010): Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor gamma coactivator 1alpha. Diabetes 59: 2315-2325.